Onkologie. 2023:17(3):197-200 | DOI: 10.36290/xon.2023.039

Minimal invasive treatment and active surveillance of renal cell carcinoma

Marie Pechová1, Vladimír Šámal1, 2, Vít Paldus1, Igor Richter3, Miroslav Šercl4
1 Urologické oddělení, Krajská nemocnice Liberec, a. s.
2 Urologická klinika, LF a FN Hradec Králové
3 Komplexní onkologické centrum, Krajská nemocnice Liberec, a. s
4 Radiologické oddělení, Krajská nemocnice Liberec, a. s.

Small Renal Masses (SRM) are defined as incidentally diagnosed, circumscribed solid or cystic tumors of the kidney < 4 cm with signs of saturation on a contrast-enhanced CT scan, corresponding to stage cT1aN0M0. In up to 60% of patients, the kidney tumor is detected incidentally. The incidence of SRM in elderly and polymorbid patients is also increasing. The standard of care for a localized kidney tumor is surgical treatment. In elderly patients or patients with serious comorbidities, SRM can only be actively monitored (Active Surveillance - AS). It is known that surgical treatment in the population over 75 years of age does not lead to a prolongation of overall survival. The AS method can be offered to informed patients over 75 years of age. AS offers the possibility of at least initial monitoring of SRM, in the case of tumor size progression it is possible to switch to active treatment. The risk of progression of SRM to metastatic disease in cohorts of patients over 75 years of age is small (1-2%). Minimally invasive methods of thermal ablation (TA) of tumors offer the possibility of solving SRM with minimization of the risk of surgical complications and only minimal deterioration of renal functions. The radiofrequency ablation (RFA) method is effective for treating SRMs up to 3 cm in size. Long-term follow-up results after RFA indicate a 5-year overall survival (OS) of 73-79%. Cryoablation is effective for treating SRM up to 4 cm in size. The success of TA methods decreases with tumor size. Long-term results are lacking for TA methods, so it is not possible to draw conclusions regarding the clinical effectiveness of TA compared to radical nephrectomy or kidney resection. Due to these uncertainties, TA methods can only be recommended for frail and/or comorbid patients with small kidney tumors.

Keywords: renal cell carcinoma, active surveillance, minimal invasive therapy, radiofrequency ablation, microwave ablation, cryoablation.

Accepted: June 12, 2023; Published: June 16, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pechová M, Šámal V, Paldus V, Richter I, Šercl M. Minimal invasive treatment and active surveillance of renal cell carcinoma. Onkologie. 2023;17(3):197-200. doi: 10.36290/xon.2023.039.
Download citation

References

  1. Vasudev NS, Wilson, M, Stewart, GD, et al. Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer. BMJ Open. 2020;10(5):e035938. Go to original source... Go to PubMed...
  2. Finelli A, Ismaila, N, Bro, B, et al. Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(6):668-680. Go to original source... Go to PubMed...
  3. Zini L, Perrotte, P, Jeldres, C, et al. A population-based comparison of survival after nephrectomy vs nonsurgical management for small renal masses. BJU Int. 2009;103(7):899-904; discussion 904. Go to original source... Go to PubMed...
  4. Xing M, Kokabi, N, Zhang, D, et al. Comparative Effectiveness of Thermal Ablation, Surgical Resection, and Active Surveillance for T1a Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked Population Study. Radiology. 2018;288(1):81-90. Go to original source... Go to PubMed...
  5. Huang WC, Pinheiro, LC, Russo, P, et al. Surveillance for the management of small renal masses: Utilization and outcomes in a population-based cohort. Journal of Clinical Oncology. 2013;31(6_suppl):343-343. Go to original source...
  6. Agbakwuru EA, Salako, AA, Olajide, AO, et al. Hydrocelectomy under local anaesthesia in a Nigerian adult population. Afr Health Sci. 2008;8(3):160-162. Go to PubMed...
  7. Volpe A, Panzarella, T, Rendon, RA, et al. The natural history of incidentally detected small renal masses. Cancer. 2004;100(4):738-745. Go to original source... Go to PubMed...
  8. Pierorazio PM, Johnson, MH, Ball, MW, et al. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. Eur Urol. 2015;68(3):408-415. Go to original source... Go to PubMed...
  9. Lane BR, Abouassaly, R, Gao, T, et al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer. 2010;116(13): 3119-3126. Go to original source... Go to PubMed...
  10. Patel N, Cranston, D, Akhtar, MZ, et al. Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy. BJU Int. 2012;110(9):1270-1275. Go to original source... Go to PubMed...
  11. Finelli A, Cheung, DC, Al-Matar, A, et al. Small Renal Mass Surveillance: Histology-specific Growth Rates in a Biopsy-characterized Cohort. Eur Urol. 2020;78(3):460-467. Go to original source... Go to PubMed...
  12. Psutka SP, Feldman, AS, McDougal, WS, et al. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma. Eur Urol. 2013;63(3):486-492. Go to original source... Go to PubMed...
  13. Johnson BA, Sorokin, I, and Cadeddu, JA. Ten-Year Outcomes of Renal Tumor Radio Frequency Ablation. J Urol. 2019;201(2):251-258. Go to original source... Go to PubMed...
  14. Chang X, Zhang, F, Liu, T, et al. Radio frequency ablation versus partial nephrectomy for clinical T1b renal cell carcinoma: long-term clinical and oncologic outcomes. J Urol. 2015;193(2):430-435. Go to original source... Go to PubMed...
  15. Yu J, Zhang, X, Liu, H, et al. Percutaneous Microwave Ablation versus Laparoscopic Partial Nephrectomy for cT1a Renal Cell Carcinoma: A Propensity-matched Cohort Study of 1955 Patients. Radiology. 2020;294(3):698-706. Go to original source... Go to PubMed...
  16. Guo J, Arellano RS. Percutaneous Microwave Ablation of Category T1a Renal Cell Carcinoma: Intermediate Results on Safety, Technical Feasibility, and Clinical Outcomes of 119 Tumors. AJR Am J Roentgenol. 2021;216(1):117-124. Go to original source... Go to PubMed...
  17. Aarts BM, Prevoo W, Meier MAJ, et al. Percutaneous Microwave Ablation of Histologically Proven T1 Renal Cell Carcinoma. Cardiovasc Intervent Radiol. 2020;43(7):1025-1033. Go to original source... Go to PubMed...
  18. Bajorin DF, Witjes, JA, Gschwend, JE, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021;384(22):2102-2114. Go to original source... Go to PubMed...
  19. Pickersgill NA, Vetter, JM, Kim, EH, et al. Ten-Year Experience with Percutaneous Cryoablation of Renal Tumors: Tumor Size Predicts Disease Progression. J Endourol. 2020;34(12):1211-1217. Go to original source... Go to PubMed...
  20. Morkos J, Porosnicu Rodriguez, KA, Zhou, A, et al. Percutaneous Cryoablation for Stage 1 Renal Cell Carcinoma: Outcomes from a 10-year Prospective Study and Comparison with Matched Cohorts from the National Cancer Database. Radiology. 2020;296(2):452-459. Go to original source... Go to PubMed...
  21. Breen DJ, King, AJ, Patel, N, et al. Image-guided Cryoablation for Sporadic Renal Cell Carcinoma: Three- and 5-year Outcomes in 220 Patients with Biopsy-proven Renal Cell Carcinoma. Radiology. 2018;289(2):554-561. Go to original source... Go to PubMed...
  22. Hebbadj S, Cazzato, RL, Garnon, J, et al. Safety Considerations and Local Tumor Control Following Percutaneous Image-Guided Cryoablation of T1b Renal Tumors. Cardiovasc Intervent Radiol. 2018;41(3):449-458. Go to original source... Go to PubMed...
  23. Grange R, Tradi, F, Izaaryene, J, et al. Computed tomography-guided percutaneous cryoablation of T1b renal tumors: safety, functional and oncological outcomes. Int J Hyperthermia. 2019;36(1):1065-1071. Go to original source... Go to PubMed...
  24. Pecoraro A, Palumbo C, Knipper S, et al. Cryoablation Predisposes to Higher Cancer Specific Mortality Relative to Partial Nephrectomy in Patients with Nonmetastatic pT1b Kidney Cancer. J Urol. 2019;202(6):1120-1126. Go to original source... Go to PubMed...
  25. Andrews JR, Atwell, T, Schmit, G, et al. Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol. 2019;76(2):244-251. Go to original source... Go to PubMed...
  26. Guazzoni G, Cestari A, Buffi N, et al. Oncologic results of laparoscopic renal cryoablation for clinical T1a tumors: 8 years of experience in a single institution. Urology. 2010;76(3):624-629. Go to original source... Go to PubMed...
  27. Larcher A, Fossati, N, Mistretta, F, et al. Long-term oncologic outcomes of laparoscopic renal cryoablation as primary treatment for small renal masses. Urol Oncol. 2015;33(1):22.e1-22.e9. Go to original source... Go to PubMed...
  28. Thompson RH, Atwell, T, Schmit, G, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol. 2015;67(2):252-259. Go to original source... Go to PubMed...
  29. Abu-Ghanem Y, Fernández-Pello, S, Bex, A, et al. Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses: A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline Panel. Eur Urol Oncol. 2020;3(4):433-452. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.